FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149133771> ?p ?o ?g. }

• W2149133771 endingPage "1228" @default.
• W2149133771 startingPage "1227" @default.
• W2149133771 abstract "Abstract Background. Preclinical studies demonstrated that non-nucleoside reverse transcriptase inhibitors used for the treatment of HIV could antagonize tumor development. This led us to assess the efficacy of efavirenz in patients with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter phase II study. Methods. We used a Simon two-stage design and a 3-month prostate-specific antigen (PSA) nonprogression rate of 40% as a primary objective. Patients received 600 mg efavirenz daily with the possibility of a dose increase in case of PSA progression. Exploratory analyses included pharmacokinetics of efavirenz plasma concentrations and correlations with clinical outcomes. Results. Among 53 assessable patients, we observed 15 instances of PSA nonprogression at 3 months, corresponding to a nonprogression rate of 28.3% (95% confidence interval: 16.8%–42.3%). The exploratory analysis revealed that for the 7 patients in whom optimal plasma concentration of efavirenz was achieved, PSA progression was observed in only 28.6% compared with 81.8% of patients with suboptimal plasma concentrations of efavirenz. Conclusion. Although 600 mg efavirenz did not statistically improve the PSA nonprogression rate, our exploratory analysis suggests that higher plasma concentrations of this drug (i.e., use of increased dosages) may be of potential benefit for the treatment of mCRPC." @default.
• W2149133771 created "2016-06-24" @default.
• W2149133771 creator A5011506675 @default.
• W2149133771 creator A5018262486 @default.
• W2149133771 creator A5024806046 @default.
• W2149133771 creator A5029622182 @default.
• W2149133771 creator A5032686530 @default.
• W2149133771 creator A5042461515 @default.
• W2149133771 creator A5052416819 @default.
• W2149133771 creator A5057183350 @default.
• W2149133771 creator A5063730530 @default.
• W2149133771 creator A5065732872 @default.
• W2149133771 creator A5072906655 @default.
• W2149133771 creator A5073671145 @default.
• W2149133771 creator A5077745138 @default.
• W2149133771 date "2014-10-29" @default.
• W2149133771 modified "2023-10-14" @default.
• W2149133771 title "A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer" @default.
• W2149133771 doi "https://doi.org/10.1634/theoncologist.2014-0345" @default.
• W2149133771 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4257751" @default.
• W2149133771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25355844" @default.
• W2149133771 hasPublicationYear "2014" @default.
• W2149133771 type Work @default.
• W2149133771 sameAs 2149133771 @default.
• W2149133771 citedByCount "29" @default.
• W2149133771 countsByYear W21491337712015 @default.
• W2149133771 countsByYear W21491337712016 @default.
• W2149133771 countsByYear W21491337712017 @default.
• W2149133771 countsByYear W21491337712018 @default.
• W2149133771 countsByYear W21491337712019 @default.
• W2149133771 countsByYear W21491337712020 @default.
• W2149133771 countsByYear W21491337712021 @default.
• W2149133771 countsByYear W21491337712022 @default.
• W2149133771 countsByYear W21491337712023 @default.
• W2149133771 crossrefType "journal-article" @default.
• W2149133771 hasAuthorship W2149133771A5011506675 @default.
• W2149133771 hasAuthorship W2149133771A5018262486 @default.
• W2149133771 hasAuthorship W2149133771A5024806046 @default.
• W2149133771 hasAuthorship W2149133771A5029622182 @default.
• W2149133771 hasAuthorship W2149133771A5032686530 @default.
• W2149133771 hasAuthorship W2149133771A5042461515 @default.
• W2149133771 hasAuthorship W2149133771A5052416819 @default.
• W2149133771 hasAuthorship W2149133771A5057183350 @default.
• W2149133771 hasAuthorship W2149133771A5063730530 @default.
• W2149133771 hasAuthorship W2149133771A5065732872 @default.
• W2149133771 hasAuthorship W2149133771A5072906655 @default.
• W2149133771 hasAuthorship W2149133771A5073671145 @default.
• W2149133771 hasAuthorship W2149133771A5077745138 @default.
• W2149133771 hasBestOaLocation W21491337711 @default.
• W2149133771 hasConcept C112705442 @default.
• W2149133771 hasConcept C121608353 @default.
• W2149133771 hasConcept C126322002 @default.
• W2149133771 hasConcept C126894567 @default.
• W2149133771 hasConcept C142462285 @default.
• W2149133771 hasConcept C143998085 @default.
• W2149133771 hasConcept C203014093 @default.
• W2149133771 hasConcept C2776551883 @default.
• W2149133771 hasConcept C2777351918 @default.
• W2149133771 hasConcept C2780192828 @default.
• W2149133771 hasConcept C2781406297 @default.
• W2149133771 hasConcept C2781432083 @default.
• W2149133771 hasConcept C2993143319 @default.
• W2149133771 hasConcept C3013748606 @default.
• W2149133771 hasConcept C44249647 @default.
• W2149133771 hasConcept C61367390 @default.
• W2149133771 hasConcept C71924100 @default.
• W2149133771 hasConceptScore W2149133771C112705442 @default.
• W2149133771 hasConceptScore W2149133771C121608353 @default.
• W2149133771 hasConceptScore W2149133771C126322002 @default.
• W2149133771 hasConceptScore W2149133771C126894567 @default.
• W2149133771 hasConceptScore W2149133771C142462285 @default.
• W2149133771 hasConceptScore W2149133771C143998085 @default.
• W2149133771 hasConceptScore W2149133771C203014093 @default.
• W2149133771 hasConceptScore W2149133771C2776551883 @default.
• W2149133771 hasConceptScore W2149133771C2777351918 @default.
• W2149133771 hasConceptScore W2149133771C2780192828 @default.
• W2149133771 hasConceptScore W2149133771C2781406297 @default.
• W2149133771 hasConceptScore W2149133771C2781432083 @default.
• W2149133771 hasConceptScore W2149133771C2993143319 @default.
• W2149133771 hasConceptScore W2149133771C3013748606 @default.
• W2149133771 hasConceptScore W2149133771C44249647 @default.
• W2149133771 hasConceptScore W2149133771C61367390 @default.
• W2149133771 hasConceptScore W2149133771C71924100 @default.
• W2149133771 hasIssue "12" @default.
• W2149133771 hasLocation W21491337711 @default.
• W2149133771 hasLocation W21491337712 @default.
• W2149133771 hasLocation W21491337713 @default.
• W2149133771 hasLocation W21491337714 @default.
• W2149133771 hasLocation W21491337715 @default.
• W2149133771 hasOpenAccess W2149133771 @default.
• W2149133771 hasPrimaryLocation W21491337711 @default.
• W2149133771 hasRelatedWork W1521531357 @default.
• W2149133771 hasRelatedWork W2309274182 @default.
• W2149133771 hasRelatedWork W2414042649 @default.
• W2149133771 hasRelatedWork W2831103683 @default.
• W2149133771 hasRelatedWork W2942985299 @default.
• W2149133771 hasRelatedWork W2971490708 @default.
• W2149133771 hasRelatedWork W2996229517 @default.

• next